cysteamine has been researched along with Huntington Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allain, P; Azulay, JP; Bachoud-Lévi, AC; Bonneau, D; Calvas, F; Charles, P; Durr, A; Goizet, C; Krystkowiak, P; Maison, P; Olivier, A; Prundean, A; Reynier, P; Saudou, F; Scherer, C; Simonin, C; Tranchant, C; Verny, C; von Studnitz, E; Youssov, K | 1 |
| Akimov, S; Arbez, N; Eddings, C; Ren, M; Roby, E; Ross, CA; Wang, X | 1 |
| Bonneau, D; Humbert, S; Prundean, A; Verny, C; Youssov, K | 1 |
| Cicchetti, F; Gibrat, C | 1 |
| Borges-Correia, A; Panayotis, N; Roux, JC; Saudou, F; Villard, L; Zala, D | 1 |
| Couzin, J | 1 |
| Cooper, AJ; Hayden, MR; Jeitner, TM; Krasnikov, BF; Leavitt, BR; Pinto, JT; Thaler, HT; Van Raamsdonk, JM | 1 |
| Dubinsky, R; Gray, C | 1 |
| Alberch, J; Borrell-Pagès, M; Brouillet, E; Bryson, EA; Canals, JM; Cheetham, ME; Cordelières, FP; Grange, G; Guillermier, M; Hantraye, P; Hirsch, E; Humbert, S; Néri, C; Parker, JA; Pineda, JR; Saudou, F | 1 |
| Frankish, H | 1 |
| Humbert, S; Saudou, F | 1 |
| Barone, P; Chase, TN; Fedio, P; Juncos, J; Mohr, E; Serrati, C; Shults, C; Steardo, L; Tamminga, CA | 1 |
1 review(s) available for cysteamine and Huntington Disease
| Article | Year |
|---|---|
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Topics: Animals; Cystamine; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Humans; Huntington Disease; Mice; Mice, Transgenic; Molecular Targeted Therapy; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Radiation-Protective Agents | 2011 |
4 trial(s) available for cysteamine and Huntington Disease
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.
Topics: Adult; Aged; Cysteamine; Cystine Depleting Agents; Delayed-Action Preparations; Double-Blind Method; Female; Follow-Up Studies; Humans; Huntington Disease; Male; Middle Aged; Treatment Outcome | 2017 |
A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease.
Topics: Adolescent; Adult; Cysteamine; Drug Tolerance; Humans; Huntington Disease; Middle Aged; Treatment Outcome; Young Adult | 2015 |
CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease.
Topics: Adult; Cysteamine; Drug Administration Schedule; Drug Tolerance; Female; Humans; Huntington Disease; Male; Middle Aged; Radiation-Protective Agents; Severity of Illness Index | 2006 |
Huntington's disease: effect of cysteamine, a somatostatin-depleting agent.
Topics: Adult; Cognition; Cysteamine; Female; Humans; Huntington Disease; Male; Middle Aged; Somatostatin | 1986 |
7 other study(ies) available for cysteamine and Huntington Disease
| Article | Year |
|---|---|
Cysteamine Protects Neurons from Mutant Huntingtin Toxicity.
Topics: Animals; Cells, Cultured; Cysteamine; Huntingtin Protein; Huntington Disease; Mice; Mutation; Neurons; Neuroprotective Agents | 2019 |
[Unexpected link between Huntington disease and Rett syndrome].
Topics: Animals; Axonal Transport; Axons; Biological Transport; Brain Stem; Brain-Derived Neurotrophic Factor; Cysteamine; Drug Evaluation, Preclinical; Gene Expression Regulation; Humans; Huntingtin Protein; Huntington Disease; Methyl-CpG-Binding Protein 2; Mice; Models, Neurological; Nerve Tissue Proteins; Nuclear Proteins; Rett Syndrome; Transcription, Genetic; Transport Vesicles | 2012 |
Huntington's disease. Unorthodox clinical trials meld science and care.
Topics: Animals; Blueberry Plants; Clinical Trials as Topic; Creatine; Cysteamine; Drug Therapy, Combination; Drug Therapy, Computer-Assisted; Fatty Acids, Omega-3; Humans; Huntington Disease; Mice; Patient Selection; Phytotherapy; Plant Extracts; Software; Trehalose; Ubiquinone | 2004 |
Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Colorimetry; Cystamine; Cysteamine; Female; Glutathione; Huntington Disease; Male; Mice; Mice, Transgenic; Taurine; Time Factors | 2005 |
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
Topics: Aged; Animals; Brain; Brain-Derived Neurotrophic Factor; Caenorhabditis elegans; Cystamine; Cysteamine; HSP40 Heat-Shock Proteins; Humans; Huntington Disease; Macaca; Mice; Mice, Transgenic; Middle Aged; Molecular Chaperones; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Transglutaminases | 2006 |
Drug shows potential for treatment of Huntington's disease.
Topics: Brain-Derived Neurotrophic Factor; Cell Death; Cystamine; Cysteamine; Enzyme Inhibitors; Humans; Huntington Disease | 2006 |
[Cysteamine restores intracellular dynamics and BDNF secretion in Huntington's disease].
Topics: Brain-Derived Neurotrophic Factor; Cysteamine; Humans; Huntington Disease; Transglutaminases | 2006 |